|
Cardiol Therapeutics inc (NASDAQ: CRDL) |
|
Cardiol Therapeutics inc
CRDL's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Cardiol Therapeutics Inc 's sales fell
in IV. Quarter 2023 from the same quarter a year ago.
Biotechnology & Pharmaceuticals industry recorded
deterioration of revenues by -1.86 %
Cardiol Therapeutics Inc net loss decreased from $-24 millions, to $-22 millions in IV. Quarter 2023,
• More on CRDL's Growth
|
|
Cardiol Therapeutics Inc realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 1.92 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.3.
• More on CRDL's Valuation
|
|
|
|
|
Cardiol Therapeutics Inc realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 1.92 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.3.
Cardiol Therapeutics Inc Price to Book Ratio is at 4.05 higher than Industry Avg. of -0, and higher than S&P 500 Avg. of 0.01
• More on CRDL's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2024 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com